12.06.2008 20:14:00
|
Millipore Announces New Bioscience Division President
Millipore Corporation (NYSE:MIL), a life science leader that provides
technologies, tools and services for bioscience research and
biopharmaceutical manufacturing, today announced that Jon DiVincenzo has
been appointed to succeed Dominique Baly as the President of its
Bioscience Division. Mr. DiVincenzo, currently the Vice President,
Global Sales and Service, for Millipore’s
Bioscience Division, will assume his new role on January 1, 2009, and
Mr. Baly will support this transition through the remainder of 2008.
"During his 36 years of service at Millipore,
Dominique has made tremendous contributions to the company,”
said Martin Madaus, Chairman & CEO of Millipore. "Most
recently Dominique led the successful creation and growth of our
Bioscience Division as a major player in Life Science research and
development. He also played a pivotal role in building our successful
Lab Water business and, for many years, led Millipore’s
expansion into emerging economies, contributing to our strong global
market position.” "We are well positioned with Jon DiVincenzo
assuming the role of President of our Bioscience Division in 2009. Under
Dominique’s guidance and mentorship, Jon has
developed into one of Millipore’s most
promising leaders. With in-depth knowledge of the Life Sciences, Drug
Discovery and Development, Lab Water and Filtration markets, Jon brings
great skill and experience to the Division President role.”
Mr. DiVincenzo joined Millipore in 1994. He holds a Bachelor of Science
degree in Mechanical Engineering from Northeastern University. Among his
many accomplishments, Mr. DiVincenzo most recently spearheaded the
integration and redeployment of the global sales and service teams as
part of Millipore’s transformational growth.
About Millipore
Millipore (NYSE: MIL) is a life science leader providing cutting-edge
technologies, tools, and services for bioscience research and
biopharmaceutical manufacturing. As a strategic partner, we collaborate
with customers to confront the world's challenging human health issues.
From research to development to production, our scientific expertise and
innovative solutions help customers tackle their most complex problems
and achieve their goals. Millipore Corporation is an S&P 500 company
with more than 6,000 employees in 47 countries worldwide.
Advancing Life Science Together™
Research. Development. Production.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu Merck KGaAmehr Nachrichten
Analysen zu Merck KGaAmehr Analysen
09:34 | Merck Overweight | JP Morgan Chase & Co. | |
02.12.24 | Merck Kaufen | DZ BANK | |
18.11.24 | Merck Overweight | JP Morgan Chase & Co. | |
15.11.24 | Merck Buy | Deutsche Bank AG | |
15.11.24 | Merck Buy | UBS AG |
Aktien in diesem Artikel
Merck KGaA | 142,15 | 0,46% |
Indizes in diesem Artikel
S&P 500 | 6 049,88 | 0,05% |